Soria JC - Search Results

1

QT interval prolongation among patients treated with angiogenesis inhibitors.

Ederhy S, Cohen A, Dufaitre G, Izzedine H, Massard C, Meuleman C, Besse B, Berthelot E, Boccara F, Soria JC. Ederhy S, et al. Among authors: soria jc. Target Oncol. 2009 Apr;4(2):89-97. doi: 10.1007/s11523-009-0111-3. Epub 2009 May 6. Target Oncol. 2009. PMID: 19418112 Review.

2

[Predicting response to Iressa: unexpected mechanism].

Besse B, Le Chevalier T, Soria JC. Besse B, et al. Among authors: soria jc. Med Sci (Paris). 2004 Aug-Sep;20(8-9):750-1. doi: 10.1051/medsci/2004208-9750. Med Sci (Paris). 2004. PMID: 15361339 Free article. French. No abstract available.

3

Front-line doublets in advanced non-small cell lung cancer: The golden age for second line chemotherapy.

Besse B, Soria JC, Le Chevalier T. Besse B, et al. Among authors: soria jc. Ann Oncol. 2005 Jul;16(7):997-8. doi: 10.1093/annonc/mdi231. Epub 2005 Jun 9. Ann Oncol. 2005. PMID: 15946975 Free article. No abstract available.

4

[EGFR-targeted therapies: what's new?].

Vignot S, Besse B, Soria JC, Milano G, Spano JP. Vignot S, et al. Among authors: soria jc. Bull Cancer. 2006 Jan;93(1):13-8. Bull Cancer. 2006. PMID: 16455501 Free article. Review. French.

5

[Treatment of cancer: surgery, radiotherapy, chemotherapy, hormonal therapy. Multidisciplinary therapeutic decision making and informing the patient].

Besse B, Soria JC. Besse B, et al. Among authors: soria jc. Rev Prat. 2007 Feb 28;57(4):429-40; quiz 440. Rev Prat. 2007. PMID: 17455746 Review. French. No abstract available.

6

Targeted therapies in lung cancer.

Besse B, Ropert S, Soria JC. Besse B, et al. Among authors: soria jc. Ann Oncol. 2007 Jul;18 Suppl 9:ix135-42. doi: 10.1093/annonc/mdm308. Ann Oncol. 2007. PMID: 17631566 Free article. Review. No abstract available.

7

[Targeting epidermal growth factor receptor in non-small cell lung cancer: current advances and perspectives].

Italiano A, Besse B, Planchard D, Soria JC. Italiano A, et al. Among authors: soria jc. Bull Cancer. 2007;94(7 Suppl):F177-88. Bull Cancer. 2007. PMID: 17964994 Review. French.

8

Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy.

Loriot Y, Perlemuter G, Malka D, Penault-Llorca F, Boige V, Deutsch E, Massard C, Armand JP, Soria JC. Loriot Y, et al. Among authors: soria jc. Nat Clin Pract Oncol. 2008 May;5(5):268-78. doi: 10.1038/ncponc1087. Epub 2008 Mar 18. Nat Clin Pract Oncol. 2008. PMID: 18349858 Review.

9

Leptomeningeal and medullary response to second-line erlotinib in lung adenocarcinoma.

Wagner M, Besse B, Balleyguier C, Soria JC. Wagner M, et al. Among authors: soria jc. J Thorac Oncol. 2008 Jun;3(6):677-9. doi: 10.1097/JTO.0b013e3181757a8b. J Thorac Oncol. 2008. PMID: 18520813 Free article. No abstract available.

10

Rhinitis and epistaxis in patients treated by anti-angiogenic therapy.

Prulière-Escabasse V, Escudier E, Balheda R, Soria JC, Coste A, Massard C. Prulière-Escabasse V, et al. Among authors: soria jc. Invest New Drugs. 2009 Jun;27(3):285-6. doi: 10.1007/s10637-008-9168-6. Epub 2008 Aug 27. Invest New Drugs. 2009. PMID: 18754078

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

732 results

Search Page